To achieve our mission and deliver on our strategy, in 2024 we announced a new business structure for the Company, which comprises five operating segments: Therapeutics, Precision Medicine, International, MedTech and Telix Manufacturing Solutions1. In this Annual Report and going forward, we will be reporting financial results by the three reportable segments: Therapeutics, Precision Medicine (including International and Medtech) and TMS.
We have also continued to evolve our business strategy in line with the maturity of the Company. Following a period of significant growth and commercial development, we have merged the strategic pillars of ‘Grow Illuccix® revenue globally’ and ‘Expand commercial imaging portfolio’ into one strategic goal of 'Grow our industry-leading Precision Medicine franchise.‘ The goal to 'Build next-generation radiopharmaceuticals’ is no longer limited to alpha theranostics, to ensure we have sufficient flexibility in our approach to innovation.
The future prospects of our growth and operational targets depend on:
Continued revenue growth of Illuccix®.
Marketing authorization and successful commercial launches of follow-on precision medicine agents: TLX007-CDx TLX101-CDx and TLX250-CDx.
Advancement of our therapeutic pipeline.
Integration and expansion of the RLS business.
Operationalization of the TMS network.
More information relating to the factors that could affect our growth and operational targets is provided in the Managing risk section of this Annual Report.
- Telix ASX disclosure 27 August 2024.